Abstracts Archive - Page 1153 of 2425 - ACR Meeting Abstracts

Abstract Number: 2227 • 2018 ACR/ARHP Annual Meeting
What Should be the Goals of Gout Therapy? a Patient Perspective
Jasvinder A. Singh, Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: In the absence of any available current evidence, our primary objective was to assess the goals of gout treatment from a patient perspective and…
Abstract Number: 2228 • 2018 ACR/ARHP Annual Meeting
A Validated Script Concordance Test Demonstrates Interdisciplinary Differences in Clinical Decision-Making When Using Allopurinol to Treat Gout in Chronic Kidney Disease
Nicholas Lebedoff¹, Sarah Gilligan¹, Andrea Barker², Curry L. Koening³, Kelly Starman⁴, Christina Gallop⁵, Bernadette C. Siaton⁶, Kalani L. Raphael^4,7 and Michael J. Battistone⁸, ¹Internal Medicine, University of Utah, Salt Lake City, UT, ²Salt Lake City VAMC and University of Utah, North Salt Lake, UT, ³Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁴Salt Lake City VA Medical Center, Salt Lake City, UT, ⁵Primary Care, Salt Lake City VA Medical Center, Salt Lake City, UT, ⁶University of Maryland, Baltimore, MD, ⁷Nephrology, University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: The safety of allopurinol in the setting of chronic kidney disease (CKD) has been a controversial issue for many years. The perceived increased risk…
Abstract Number: 2229 • 2018 ACR/ARHP Annual Meeting
Can We Predict Inadequate Response to Allopurinol Dose Escalation? Analysis of a Randomized Controlled Trial
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: The two most common causes of inadequate serum urate (SU) lowering with allopurinol are low adherence and under-dosing. Those who are adherent, but do…
Abstract Number: 2230 • 2018 ACR/ARHP Annual Meeting
Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?
Estella Yeo¹, Suetonia Palmer², Peter T. Chapman³, Christopher Frampton⁴ and Lisa K. Stamp⁴, ¹Canterbury District Health Board, Christchurch, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³Christchurch Hospital, Christchurch, New Zealand, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: To explore the number of patients on haemodialysis (HD) or peritoneal dialysis (PD) with gout in Canterbury and to determine how many were receiving…
Abstract Number: 2231 • 2018 ACR/ARHP Annual Meeting
An Ancestral-Specific Interaction of TRIM46 with a Past-History of Smoking May Influence Gout Risk
Niamh Fanning¹, Tony R. Merriman², Amanda Phipps-Green², John Pearson³, Ruth Topless², Murray Cadzow², Douglas White⁴, Nicola Dalbeth⁵ and Lisa K. Stamp⁶, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴Department of Rheumatology, Waikato Clinical School, Hamilton, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Otago, Christchurch, New Zealand
Background/Purpose: Gout is caused by an interplay of genetic and environmental factors. Epidemiological and prospective studies suggest that current-smoking may be protective for developing gout…
Abstract Number: 2232 • 2018 ACR/ARHP Annual Meeting
Prevalence of Gout in the Surviving U.S. Solid Organ Transplant Population
Mark D. Brigham¹, Thilan Tudor¹, Gavin Miyasato¹, Jeffrey D. Kent², Brian LaMoreaux³ and Brian F. Mandell⁴, ¹Trinity Partners, Waltham, MA, ²Medical Affairs, Horizon Pharma USA, Inc, Lake Forest, IL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Although incidence and survival are frequent topics within the solid organ transplant (SOT) literature, there are no recent publications on the total size of…
Abstract Number: 2233 • 2018 ACR/ARHP Annual Meeting
Activation and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Gouty Arthritis
Yong-Wook Park¹, Young-Nan Cho², Hye-Mi Jin¹ and Seung-Jung Kee³, ¹Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South), ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, MN, Korea, Republic of (South), ³Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South)
Background/Purpose: Mucosal-associated invariant T (MAIT) cells contribute to protection against certain microorganism infections and play an important role in mucosal immunity. Upon antigen recognition, MAIT…
Abstract Number: 2234 • 2018 ACR/ARHP Annual Meeting
Liver Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
Jung Sun Lee¹, Seokchan Hong², Jebum Won¹, Oh Chan Kwon², Ji Seon Oh², Yong-Gil Kim², Chang Keun Lee² and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine,, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Although febuxostat has been widely used for lowering uric acid levels because of its renal safety compared with allopurinol, data on the hepatic safety…
Abstract Number: 2235 • 2018 ACR/ARHP Annual Meeting
Monosodium Urate Deposition Distribution in the Knees, Hands, and Feet of Treated Gout Patients: A Dual-Energy CT Study
Chio Yokose¹, Nicola Dalbeth², Savvas Nicolaou³, Scott Baumgartner⁴, Jia Hu⁵, Maple Fung⁴, F. Joseph Simeone⁶ and Hyon K. Choi¹, ¹Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ²University of Auckland, Auckland, New Zealand, ³Radiology, University of British Columbia, Vancouver, BC, Canada, ⁴Formerly Ardea Biosciences, San Diego, CA, ⁵Heron Therapeutics, San Diego, CA, ⁶Department of Radiology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Prior studies have demonstrated that monosodium urate (MSU) deposits on dual-energy CT (DECT) are commonly found in joints as well as tendons of the…
Abstract Number: 2236 • 2018 ACR/ARHP Annual Meeting
Contemporary Comorbidity Burden of Gout and Hyperuricemia in the US during the Past Decade (National Health And Nutrition Examination Survey [NHANES] 2007-2016)
Michael Chen-Xu¹, Chio Yokose², Michael Pillinger³ and Hyon K. Choi², ¹General Medicine, Wairarapa District Health Board, Masterton, New Zealand, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Medicine/Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Precise estimates of the comorbidity burden of gout and hyperuricemia are critical as their presence has important implications for the treatment of both gout…
Abstract Number: 2237 • 2018 ACR/ARHP Annual Meeting
Prevalence of Urate-Lowering Therapy Use and Target Urate Level Achievement Among Gout Patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014)
Michael Chen-Xu¹, Chio Yokose², Michael Pillinger³ and Hyon K. Choi², ¹General Medicine, Wairarapa District Health Board, Masterton, New Zealand, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Medicine/Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: To determine the latest national prevalence of urate-lowering therapy (ULT) use and achievement of a therapeutic target serum urate level (SUL) in gout patients,…
Abstract Number: 2238 • 2018 ACR/ARHP Annual Meeting
Non-Coding Urate-Associated Variants Function in a Conserved Lincrna Regulatory Domain That Alters MAF transcription
Megan Leask¹, Tony R. Merriman¹, Amy Dowdle¹, Hamish Salvesen¹, Ruth Topless¹, Tayaza Fadason², Wenhua Wei¹, William Schierding², Justin O'Sullivan² and Julia Horsfield¹, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand
Background/Purpose: Genome-wide association studies (GWAS) have revealed that the large majority of disease-associated single nucleotide polymorphisms (SNPs) are located in the non-coding regions of the…
Abstract Number: 2239 • 2018 ACR/ARHP Annual Meeting
Tenocytes Extracted from Rotator Cuff Tendons Are Able to Induce Mineral Deposition in Vitro and Express Genes Related to a Chondrocyte Differentiation
Christelle Darrieutort-Laffite^1,2, Paul Arnolfo¹, Benoit Le Goff^1,2 and Frédéric Blanchard¹, ¹INSERM U1238, PHY-OS Laboratory, Nantes, France, ²Rheumatology, Nantes University Hospital, Nantes, France
Background/Purpose: Calcific tendonitis is a frequent cause of shoulder pain. The calcium deposits are composed of carbonated apatite and their origin stays still largely unknown.…
Abstract Number: 2240 • 2018 ACR/ARHP Annual Meeting
Hip Involvement in Patients with Gout: Results of an Ultrasound Study
Andrea Di Matteo¹, Emilio Filippucci¹, Edoardo Cipolletta², Alice Musca³, María Victoria Martire⁴, Daniele Pierucci¹, Eleonora Di Donato¹ and Walter Grassi¹, ¹Polytechnic University of Marche, Rheumatology Clinic, Jesi, Italy, ²Polytechnic University of Marche, Rheumatology Clinic, jesi, Italy, ³Internal Medicine and Rheumatology Department, Bucharest, Romania, ⁴Instituto Médico Platense, La Plata, Argentina
Background/Purpose: Although considered as uncommon, the hip represents one of the possible targets of gout. To date, hip involvement in patients with gout has been…
Abstract Number: 2241 • 2018 ACR/ARHP Annual Meeting
What Can Variation in Clinical Practice Teach Us about Treatment Strategies for Patients with Gout?
Ritch te Kampe¹, Caroline van Durme¹, Matthijs Janssen², Annelies Boonen¹ and Tim Jansen², ¹Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands, Maastricht, Netherlands, ²Department of Rheumatology, VieCuri Medical Center, Venlo, The Netherlands, Venlo, Netherlands
Background/Purpose: To improve quality of care for patients with gout, two hospitals in the Netherlands initiated a protocolized gout clinic. One clinic adopted a patient-centred…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].